### Analysis of rs113488022 and Its Influence on Clinical Phenotypes

The variant **rs113488022** is located in the **BRAF gene** on chromosome 7 at position 140753336. This gene encodes a serine/threonine-protein kinase involved in the MAPK/ERK signaling pathway, which regulates cell division, differentiation, and secretion. Variants in BRAF, including rs113488022, are associated with various clinical phenotypes, particularly cancers and developmental syndromes.

---

### 1. **Variant Identification**
- **rs Number**: [rs113488022](https://identifiers.org/dbsnp/rs113488022)
- **Gene**: BRAF
- **HGVS Notations**:
  - Genomic: `chr7:g.140753336A>C`, `chr7:g.140753336A>G`, `chr7:g.140753336A>T`
  - Protein: Multiple changes depending on the transcript, including:
    - `p.Val600Gly` (A>C)
    - `p.Val600Ala` (A>G)
    - `p.Val600Glu` (A>T)
- **Transcript Examples**:
  - ENST00000288602.11:c.1919T>G (p.Val640Gly)
  - NM_004333.6:c.1799T>A (p.Val600Glu)

---

### 2. **Disease Associations**
The clinical significance of rs113488022 varies depending on the specific nucleotide change (A>C, A>G, or A>T). Below are the key associations:

#### a. **A>C (e.g., p.Val600Gly)**
- **Diseases**:
  - **RASopathy** (e.g., Cardio-facio-cutaneous syndrome)
  - **Melanoma**
  - **Squamous cell carcinoma of the colon**
- **Clinical Significance**:
  - Pathogenic (P) for RASopathy and melanoma
  - Likely pathogenic (LP) for other cancers
- **Predictive Models**:
  - SIFT: 0.0 (deleterious)
  - PolyPhen: 0.958 (probably damaging)
  - AlphaMissense: 0.9773 (high pathogenicity)

#### b. **A>G (e.g., p.Val600Ala)**
- **Diseases**:
  - **Melanoma**
- **Clinical Significance**:
  - Likely pathogenic (LP)
- **Predictive Models**:
  - SIFT: 0.0 (deleterious)
  - PolyPhen: 0.847 (probably damaging)
  - AlphaMissense: 0.9748 (high pathogenicity)

#### c. **A>T (e.g., p.Val600Glu)**
- **Diseases**:
  - **Papillary thyroid carcinoma**
  - **Non-small cell lung carcinoma**
  - **Colorectal cancer**
  - **Glioblastoma**
- **Clinical Significance**:
  - Pathogenic (P) for multiple cancers
  - Likely pathogenic (LP) for glioblastoma
- **Predictive Models**:
  - SIFT: 0.0 (deleterious)
  - PolyPhen: 0.935 (probably damaging)
  - AlphaMissense: 0.9927 (high pathogenicity)

---

### 3. **Literature Evidence**
- Variants at codon 600 of BRAF (e.g., p.Val600Glu) are well-documented in the literature as drivers of oncogenesis, particularly in melanoma and thyroid cancer.
- The p.Val600Glu mutation is a hotspot mutation that leads to constitutive activation of the BRAF kinase, driving uncontrolled cell proliferation.

---

### 4. **Allele Frequency Comparison**
- **Global Frequency**: Rare in the general population.
- **gnomAD Exomes**: 
  - Allele frequency: 1.37 × 10⁻⁶
  - Observed in 2 out of 1,460,618 alleles.
- **Japanese Population**: No specific data available for this variant in Japanese populations.

---

### 5. **GWAS Findings**
No specific GWAS findings are directly linked to rs113488022. However, variants in BRAF, particularly at codon 600, are strongly associated with cancer phenotypes in functional studies.

---

### 6. **TogoVar Link**
- [TogoVar rs113488022](https://togovar.org/variant/rs113488022)

---

### **Conclusion**
The clinical phenotype associated with rs113488022 depends on the specific nucleotide change and its effect on the BRAF protein. Variants at codon 600 (e.g., p.Val600Glu, p.Val600Ala, p.Val600Gly) are pathogenic and linked to cancers such as melanoma, thyroid carcinoma, and colorectal cancer. These mutations activate the MAPK/ERK pathway, leading to oncogenesis.

---

### 日本語での説明

### 1. **バリアントの特定**
- **rs番号**: [rs113488022](https://identifiers.org/dbsnp/rs113488022)
- **遺伝子**: BRAF
- **HGVS表記**:
  - ゲノム: `chr7:g.140753336A>C`, `chr7:g.140753336A>G`, `chr7:g.140753336A>T`
  - タンパク質: 
    - `p.Val600Gly` (A>C)
    - `p.Val600Ala` (A>G)
    - `p.Val600Glu` (A>T)
- **トランスクリプト例**:
  - ENST00000288602.11:c.1919T>G (p.Val640Gly)
  - NM_004333.6:c.1799T>A (p.Val600Glu)

---

### 2. **疾患との関連**
rs113488022の臨床的意義は、特定の塩基変化（A>C, A>G, A>T）によって異なります。

#### a. **A>C (例: p.Val600Gly)**
- **疾患**:
  - **RASopathy**（例: 心顔皮症候群）
  - **メラノーマ**
  - **結腸の扁平上皮癌**
- **臨床的意義**:
  - RASopathyおよびメラノーマに対して病原性（P）
  - 他の癌に対して病原性の可能性が高い（LP）
- **予測モデル**:
  - SIFT: 0.0（有害）
  - PolyPhen: 0.958（おそらく有害）
  - AlphaMissense: 0.9773（高い病原性）

#### b. **A>G (例: p.Val600Ala)**
- **疾患**:
  - **メラノーマ**
- **臨床的意義**:
  - 病原性の可能性が高い（LP）
- **予測モデル**:
  - SIFT: 0.0（有害）
  - PolyPhen: 0.847（おそらく有害）
  - AlphaMissense: 0.9748（高い病原性）

#### c. **A>T (例: p.Val600Glu)**
- **疾患**:
  - **乳頭状甲状腺癌**
  - **非小細胞肺癌**
  - **大腸癌**
  - **神経膠芽腫**
- **臨床的意義**:
  - 多くの癌に対して病原性（P）
  - 神経膠芽腫に対して病原性の可能性が高い（LP）
- **予測モデル**:
  - SIFT: 0.0（有害）
  - PolyPhen: 0.935（おそらく有害）
  - AlphaMissense: 0.9927（高い病原性）

---

### 3. **文献的証拠**
- BRAFのコドン600（例: p.Val600Glu）の変異は、特にメラノーマや甲状腺癌における発癌ドライバーとして広く文献で報告されています。
- p.Val600Glu変異は、BRAFキナーゼを恒常的に活性化し、制御不能な細胞増殖を引き起こします。

---

### 4. **アレル頻度の比較**
- **全体頻度**: 一般集団では稀。
- **gnomAD Exomes**: 
  - アレル頻度: 1.37 × 10⁻⁶
  - 1,460,618アレル中2例で観察。
- **日本人集団**: このバリアントに関する具体的なデータはありません。

---

### 5. **GWASの発見**
rs113488022に直接関連するGWASの発見はありません。ただし、BRAFのコドン600の変異は、機能的研究で癌表現型と強く関連しています。

---

### 6. **TogoVarリンク**
- [TogoVar rs113488022](https://togovar.org/variant/rs113488022)

---

### **結論**
rs113488022に関連する臨床表現型は、特定の塩基変化とそれがBRAFタンパク質に与える影響に依存します。コドン600（例: p.Val600Glu, p.Val600Ala, p.Val600Gly）の変異は病原性があり、メラノーマ、甲状腺癌、大腸癌などの癌と関連しています。これらの変異はMAPK/ERK経路を活性化し、発癌を引き起こします。